Research graph
References from Lacticaseibacillus rhamnosus GG enhances gefitinib efficacy and reduces treatment-related toxicity via propionyl-L-carnitine regulation. Local targets link to admitted publications; unresolved targets remain external evidence.
Non-small-cell lung cancer
10.1038/s41572-024-00551-9 · 2024 · External reference
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
10.1016/s0140-6736(26)00966-9 · 2026 · External reference
Gefitinib (an EGFR tyrosine kinase inhibitor) plus anlotinib (an multikinase inhibitor) for untreated, EGFR-mutated, advanced non-small cell lung cancer (FL-ALTER): a multicenter phase III trial
10.1038/s41392-024-01927-9 · 2024 · External reference
Efficiency and safety of sintilimab-based induction therapy in potentially resectable stage III non-small cell lung cancer (LungMate-009): an open-label, phase 2 trial
10.1016/j.eclinm.2025.103669 · 2025 · External reference
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 · External reference
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
10.1056/nejmoa0810699 · 2009 · External reference
Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management
10.1038/s41392-023-01469-6 · 2023 · External reference
Gut microbiota alters drug metabolism and therapeutic outcomes
10.1016/j.chom.2026.06.001 · 2026 · External reference
Activity of GPCR-targeted drugs influenced by human gut microbiota metabolism
10.1038/s41557-025-01789-w · 2025 · External reference
Mapping human microbiome drug metabolism by gut bacteria and their genes
10.1038/s41586-019-1291-3 · 2019 · External reference
Exploring Drug Metabolism by the Gut Microbiota: Modes of Metabolism and Experimental Approaches
10.1124/dmd.121.000669 · 2022 · External reference
The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic
10.1038/nrgastro.2014.66 · 2014 · External reference
Probiotics mitigate non-antibiotic drug-induced dysbiosis via protein homology-driven competitive binding
10.1038/s41467-026-72592-5 · 2026 · External reference
High-resolution analyses of associations between medications, microbiome, and mortality in cancer patients
10.1016/j.cell.2023.05.007 · 2023 · External reference
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response
10.1126/science.aaz7015 · 2021 · External reference
Calenduloside E produced by Bifidobacterium animalis B960 increases glibenclamide efficacy and alleviates drug-induced adverse effects in a type 2 diabetes model
10.1016/j.scib.2025.12.046 · 2026 · External reference
A historical and proteomic analysis of botulinum neurotoxin type/G
10.1186/1471-2180-11-232 · 2011 · External reference
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
10.1016/s1470-2045(09)70364-x · 2010 · External reference
10.1200/jco.2014.32.15_suppl.8117
10.1200/jco.2014.32.15_suppl.8117 · 2014 · External reference
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis
2019 · External reference
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
10.1056/nejmoa0909530 · 2010 · External reference
Navigating First-Line Treatment Options for Patients With Epidermal Growth Factor Receptor–Positive Non–Small Cell Lung Cancer
10.1200/edbk-25-472784 · 2025 · External reference
Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung Cancer
10.1001/jamaoncol.2018.1395 · 2018 · External reference
Unresolved reference
2025 · External reference
Personalized Mapping of Drug Metabolism by the Human Gut Microbiome
10.1016/j.cell.2020.05.001 · 2020 · External reference
Effects of microbiota on anticancer drugs: Current knowledge and potential applications
10.1016/j.ebiom.2022.104197 · 2022 · External reference
Disrupted propionate metabolism evokes transcriptional changes in the heart by increasing histone acetylation and propionylation
10.1038/s44161-023-00365-0 · 2023 · External reference
Fasting alleviates metabolic alterations in mice with propionyl-CoA carboxylase deficiency due to Pcca mutation
10.1038/s42003-024-06362-8 · 2024 · External reference
Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy
10.1053/j.gastro.2022.10.018 · 2023 · External reference
Lactobacillus rhamnosus GG-supplemented formula expands butyrate-producing bacterial strains in food allergic infants
10.1038/ismej.2015.151 · 2016 · External reference
Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade
10.1136/gutjnl-2020-323426 · 2022 · External reference
Chemo-immunotherapeutic potential of Lactobacillus rhamnosus GG and its bioengineering for cancer therapy
10.1016/j.biomaterials.2025.123848 · 2026 · External reference
Lactobacillus rhamnosus GG ameliorates triptolide-induced liver injury through modulation of the bile acid-FXR axis
10.1016/j.phrs.2024.107275 · 2024 · External reference
